Hem › Juvenil myelomonocyt leukemi › District of Columbia › Washington
Kliniska studier för Juvenil myelomonocyt leukemi i Washington, DC
3 studier för Juvenil myelomonocyt leukemi söker deltagare vid platser i och runt Washington (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
RekryterarFas 1/2
- Children's National Medical Center, Washington D.C.
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
RekryterarFas 1
- Children's National Medical Center, Washington D.C.
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RekryterarFas 1/2
- Children's National Medical Center, Washington D.C.
Juvenil myelomonocyt leukemi-studier i andra städer
- Philadelphia, PA4 studier
- Minneapolis, MN4 studier
- Boston, MA3 studier
- San Francisco, CA3 studier
- Indianapolis, IN3 studier
- Cincinnati, OH3 studier
- Atlanta, GA3 studier
- Memphis, TN3 studier
- Chicago, IL3 studier
- New York City, NY3 studier
- Ann Arbor, MI3 studier
- Seattle, WA3 studier
Andra studier i Washington
- Cancer (alla typer)58 studier
- Icke-småcellig lungcancer55 studier
- Bröstcancer46 studier
- Metastaserande cancer43 studier
- Lungcancer41 studier
- Prostatacancer38 studier
- Övervikt33 studier
- Kolorektal cancer29 studier
- Hjärt-kärlsjukdom28 studier
- Blåscancer26 studier
- Akut myeloid leukemi24 studier
- Äggstockscancer23 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.